- Home
- LTM vs VKTX Comparison
LTM vs VKTX Comparison
Compare LTM & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTM
- VKTX
- Stock Information
- Founded
- LTM 1929
- VKTX 2012
- Country
- LTM Chile
- VKTX United States
- Employees
- LTM N/A
- VKTX N/A
- Industry
- LTM
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- LTM
- VKTX Health Care
- Exchange
- LTM NYSE
- VKTX Nasdaq
- Market Cap
- LTM 8.0B
- VKTX 7.2B
- IPO Year
- LTM N/A
- VKTX 2015
- Fundamental
- Price
- LTM $27.75
- VKTX $61.33
- Analyst Decision
- LTM Strong Buy
- VKTX Strong Buy
- Analyst Count
- LTM 3
- VKTX 10
- Target Price
- LTM $36.67
- VKTX $108.60
- AVG Volume (30 Days)
- LTM 174.1K
- VKTX 2.1M
- Earning Date
- LTM 01-01-0001
- VKTX 10-23-2024
- Dividend Yield
- LTM 0.00%
- VKTX N/A
- EPS Growth
- LTM N/A
- VKTX N/A
- EPS
- LTM 0.00
- VKTX N/A
- Revenue
- LTM $12,486,502,000.00
- VKTX N/A
- Revenue This Year
- LTM $14.18
- VKTX N/A
- Revenue Next Year
- LTM $6.24
- VKTX N/A
- P/E Ratio
- LTM $11.31
- VKTX N/A
- Revenue Growth
- LTM 16.98
- VKTX N/A
- 52 Week Low
- LTM $21.83
- VKTX $8.28
- 52 Week High
- LTM $27.72
- VKTX $99.41
- Technical
- Relative Strength Index (RSI)
- LTM N/A
- VKTX 46.26
- Support Level
- LTM N/A
- VKTX $61.30
- Resistance Level
- LTM N/A
- VKTX $66.27
- Average True Range (ATR)
- LTM 0.00
- VKTX 3.12
- MACD
- LTM 0.00
- VKTX -0.29
- Stochastic Oscillator
- LTM 0.00
- VKTX 9.81
About LTM LATAM AIRLINES GROUP SA SPON ADS EACH REP 2000 SHS
LATAM Airlines Group SA operates as a passenger airline group. Geographically, the company operates in Brazil, Chile, Colombia, Ecuador, and Peru, along with international operations within Latin America and to Europe, the US, and the Caribbean. The firm generates its revenue from transporting passengers and cargo.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.